

FORM PTO-1449/A and B (Modified)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.: 10/695,667	ATTY. DOCKET NO.: P0741.70006US00
FILING DATE: October 27, 2003	CONFIRMATION NO.: 4456
APPLICANT: Maddon et al.	
GROUP ART UNIT: 1644	EXAMINER: Not Yet Assigned

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
SR	*A1	5,804,602		Slusher et al.	09-08-1998
	*A2	6,107,090		Bander	08-22-2000
	A3	2004/0033229	A1	Maddon et al.	02-19-2004

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
SR	*B1	WO	97/35616	A1	Pacific Northwest Cancer Foundation	10-02-1997	
SR	*B2	WO	03/034903	A2	PSMA Development Company, L.L.C.	05-01-2003	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)


EXAMINE R

DATE CONSIDERED

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/395,894, filed March 21, 2003, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

<div style="text-align: center;">  <p>FORM PTO-1449/A and B (modified PTO/SB/08)</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> </div>		APPLICATION NO.: 10/695,667	ATTY. DOCKET NO.: P0741.70006US00
		FILING DATE: October 27, 2003	CONFIRMATION NO.: 4456
		APPLICANT: Maddon et al.	
		GROUP ART UNIT: 1643	EXAMINER: Stephen L. Rawlings
Sheet	1	of	2

U.S. PATENT DOCUMENTS


Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
SR	A4	2005-0215472	A1	Schülke et al.	09-29-2005

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
SR	C1	BARINKA et al., Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J Neurochem. 2002 Feb;80(3):477-87.	
	C2	MA et al., PSMA-targeted toxin- and radio-labelled antibody therapies for prostate cancer. J Urology. 2003 Apr;169(4):211. Poster 817.	
	C3	MA et al., Fully human anti-PSMA antibodies for prostate cancer therapy. Proceedings of the American Association for Cancer Research Annual Meeting, 2003 July;44:1295. Poster 6471.	
	C4	SCHÜLKE et al., The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12590-5.	
	C5	SCHÜLKE et al., Human Prostate Specific Membrane Antigen (PSMA) is expressed as a non-covalent dimer and provides an attractive target for cancer immunotherapy. Eur J Cancer. 2002 Nov;38:S153. Poster 510.	

EXAMINER: 	DATE CONSIDERED: 2/7/07
-----------------------------------------------------------------------------------------------	-------------------------


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/695,667	ATTY. DOCKET NO.: P0741.70006US00
				FILING DATE: October 27, 2003	CONFIRMATION NO.: 4456
				APPLICANT: Maddon et al.	
				GROUP ART UNIT: 1643	EXAMINER: Stephen L. Rawlings
Sheet	2	of	2		

SR	C6	SOKOLOFF et al., A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate. 2000 May 1;43(2):150-7.	
	C7	SPENO et al., Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II. Mol Pharmacol. 1999 Jan;55(1):179-85.	
	C8	TROYER et al., Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995 Sep 4;62(5):552-8.	
	C9	XIAO et al., Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay. Protein Expr Purif. 2000 Jun;19(1):12-21.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
	2/7/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.